Berkshire Hathaway leans on a huge cash pile, low debt, and a long history of patient deal-making to hold up through rough markets and pounce on opportunities. The bigger question now is whether the handoff from Warren Buffett to Greg Abel keeps that steady approach working as the world changes.Read more

By: The Forensic Analyst | Simply Wall St In the chaotic world of equity markets, price and value often diverge. But rarely do they divorce as violently as we are currently seeing with Ubisoft Entertainment SA (UBI.PA).Read more

01 Quantum Inc. (formerly 01 Communique) has spent nearly a decade in quiet R&D, positioning itself as a first-to-market provider of software designed to protect the digital world from the existential threat of quantum computers.Read more

QuantumScape aims to make electric car batteries that can charge much faster, last longer, and be safer, using a new ceramic-based design that could change what drivers expect from an EV. The big question is whether it can reliably scale this lab-proven tech into mass production through its Volkswagen partnership before rivals catch up.Read more

Beam Therapeutics is betting that a newer, more precise form of gene editing can fix genetic diseases without the DNA damage risks tied to older approaches. Early human results in a liver-targeted program, plus a push to remove harsh chemotherapy from stem cell transplants, could open much larger patient groups—but competition and clinical execution still matter.Read more

IonQ claims it has crossed a key technical hurdle and now has the resources to push from lab promise toward real-world quantum machines. The big question is whether its room‑temperature approach and recent buyouts can turn into large deals with tech giants—or whether execution stumbles derail the story.Read more

Kodiak AI aims to sell self-driving capability to trucking fleets as a service, letting customers own the trucks while Kodiak provides the driving system and support. Big-name investors are buying in, but the company still faces a race to scale real-world driverless operations before it needs more funding—and shareholders could get watered down if it succeeds.Read more

Schrödinger blends drug research with powerful chemistry software used by many big pharmaceutical companies, creating a business that can fund its own next medicines. The near-term story hinges on upcoming trial results and new partnerships that could prove whether its approach can speed up discovery—or expose the usual drug-development setbacks.Read more

Microsoft looks like the kind of business you can own for years: it already sits at the center of work software and cloud services, and it has new bets that could add to that strength over time. The big question is whether the market is overlooking its longer-term upside from next‑generation computing, cloud expansion, and a larger gaming ecosystem.Read more